Open AccessSalvage high dose-rate brachytherapy for local recurrence of prostate cancer after different types of radical treatment
Author(s) -
V. А. Solodkiy,
Alexander Pavlov,
А. Д. Цыбульский,
А. Г. Дзидзария,
Aleksandr Pchelintsev
Publication year - 2019
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2019-15-2-73-76
Subject(s) - medicine , brachytherapy , prostate cancer , biochemical recurrence , urology , salvage therapy , survival rate , prostate specific antigen , prostate , cancer , oncology , radiation therapy , chemotherapy , prostatectomy
Objective: at the primary analysis of prostate cancer treatment referring to the patients who have experienced high dose rate brachytherapy after a confirmed locally recurrent tumor having been treated with diverse treatment modes. Materials and methods . The research includes 28 patients aged 53 to 78 years old (average age is 66 years old) with histologically verified prostate cancer recurrence. Within the period 2015–2017 all the patients got a salvage high dose rate brachytherapy in the Russian Scientific Center of Roentgenradiology. Brachytherapy was carried out as 2 fractions with the single tumor dose of 12.5 Gy. There was a two-week gap between fractions with the total tumor dose of 25 Gy. The follow-up period is 9 to 36 months. Results and conclusion. Overall biochemical free survival rate is 82.1 %. There are 5 people having a growing prostatic specific antigen (PSA) while the case follow-up. There is 1 case of a confirmed local tumor recurrence. Significant factors of the disease progression after salvage brachytherapy are: risk group, pretreatment PSA high, time line from the background therapy to biochemical recurrence uprise and PSA level if there’s prostate cancer recurrence after the background therapy.